undamentalytics Newsletter
Sign in

Lensar, Inc. income statement

In fiscal 2025, Lensar, Inc. reported revenue of $58.4m, up 9.2% on the year before, operating income of −$24.6m (a -42.1% margin) and net income of −$34.3m, or −$2.87 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue3126343542535860
Cost of revenue1712171521283131
Gross profit1314182021262729
Research and development8812126565
Selling, general and administrative1724242726264531
Operating income−13−19−20−20−12−11−25−8
Interest expense21——————
Provision for credit losses—−0000−0−0−0
Income before tax−15−20−20−20−14−31−34—
Net income−15−20−20−20−14−31−3435
Diluted EPS−$6.85−$2.14−$2.09−$1.96−$1.31−$2.73−$2.87$2.22
Diluted shares (average)2m9m9m10m11m12m12m16m
EBITDA−10−17−18−18−10−8−21−4

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CVRX vs LNSRAPT vs LNSRAPYX vs LNSR

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Lensar, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lensar, Inc.